

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7103835

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	BIOTHERYX, INC.	12/21/2021
RECEIVING PARTY DATA		
Name:	BIOTHERYX, INC.	
Street Address:	7966 ARJONS DRIVE, SUITE D	
City:	SAN DIEGO	
State/Country:	CALIFORNIA	
Postal Code:	92126	
Name:	NEUROTHERYX CANADA LTD.	
Street Address:	661 UNIVERSITY AVENUE, SUITE 1368	
City:	TORONTO	
State/Country:	CANADA	
Postal Code:	M5G1M1	
PROPERTY NUMBERS Total: 10		
Property Type	Number	
Application Number:	62014016	
Application Number:	14738652	
Application Number:	15389182	
PCT Number:	US2015035506	
Application Number:	62239783	
Application Number:	15288780	
Application Number:	62337256	
Application Number:	15595199	
Application Number:	16298868	
PCT Number:	US2017032599	
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	8583866878	

PATENT

Email: lyu@junivip.com
Correspondent Name: LIN YU
Address Line 1: 11597 TREE HOLLOW LANE
Address Line 4: SAN DIEGO, CALIFORNIA 92128

ATTORNEY DOCKET NUMBER:	129A
NAME OF SUBMITTER:	LIN YU
SIGNATURE:	/Lin Yu/
DATE SIGNED:	01/04/2022

Total Attachments: 7

source=2021-12-21_Assignment_BT_X_to_NT_X#page1.tif
source=2021-12-21_Assignment_BT_X_to_NT_X#page2.tif
source=2021-12-21_Assignment_BT_X_to_NT_X#page3.tif
source=2021-12-21_Assignment_BT_X_to_NT_X#page4.tif
source=2021-12-21_Assignment_BT_X_to_NT_X#page5.tif
source=2021-12-21_Assignment_BT_X_to_NT_X#page6.tif
source=2021-12-21_Assignment_BT_X_to_NT_X#page7.tif

ASSIGNMENT

WHEREAS BioTheryX, Inc. ("BTX"), whose full post office address is **20 Cabin Ridge Road, Chappaqua, New York 10514, U.S.A.** (hereinafter "**Assignor**"), has an ownership and interest in the inventions in the patents and patent applications set forth in Schedule 1 attached hereto;

AND WHEREAS NeuroTheryX Canada Ltd. ("NTX"), whose full post office address is **661 University Avenue, Suite 1368, Toronto, Ontario M5G 1M1, Canada** (hereinafter "**Assignee**"), is desirous of obtaining Assignor's entire right, title and interest in, to and under the said inventions, the said patents, and the said patent applications:

NOW THEREFORE, in consideration of good and valuable consideration, the receipt of which is hereby acknowledged, the Assignor hereby has sold, assigned, transferred and set over, and by these presents does hereby sell, assign, transfer, and set over, unto the said Assignee, its successors, legal representatives and assigns, the Assignor's entire right, title and interest in, to and under the said inventions, the said patents, and the said patent applications, and all divisions, renewals and continuations thereof, and all Patents of the United States which may be granted thereon and all reissues and extensions thereof; and all applications for industrial property protection, including, without limitation, all applications for patents, utility models, and designs which may be filed for said inventions in the United States or any country or countries foreign to the United States, together with the right to file such applications and the right to claim for the same the priority rights derived from said applications under the Patent Laws of the United States, the International Convention for the Protection of Industrial Property, or any other international agreement or the domestic laws of the country in which any such applications are filed, as may be applicable; and all forms of industrial property protection, including, without limitation, patents, utility models, inventors' certificates and designs which may be granted for said inventions in the United States or any country or countries foreign to the United States and all extensions, renewals and reissues thereof; and all rights to sue for infringement including past infringement.

AND the Assignor hereby authorizes and requests the Commissioner for Patents and any Official of any country or countries foreign to the United States, whose duty it is to issue patents or other evidence or forms of industrial property protection on applications as aforesaid, to issue the same to the said Assignee, its successors, legal representatives and assigns, in accordance with the terms of this instrument.

AND the Assignor hereby covenants and agrees that the Assignor has full right to convey the entire interest herein assigned, and that the Assignor has not executed, and will not execute, any agreement in conflict herewith.

AND the Assignor further covenants and agrees that the Assignor hereby will communicate to the said Assignee, its successors, legal representatives and assigns, any facts known to the Assignor respecting said inventions, and testify in any legal proceeding, sign all lawful papers, execute all divisional, continuing, reissue and foreign applications, make all rightful oaths, and generally do everything possible to aid the said Assignee, its successors, legal representatives and assigns, to obtain and enforce proper protection for the said inventions in all countries.

This Assignment shall be effective upon the date of signature of the last to sign of the Assignor and the Assignee.

This Assignment may be executed in any number of counterparts, each of which when executed shall constitute a duplicate original, but all the counterparts together shall constitute the one agreement.

This Assignment, including any non-contractual disputes or claims, shall be governed by and construed in accordance with the laws of the State of New York and each party irrevocably submits to the jurisdiction and venue of any state or federal court located within New York County, State of New York.

Signed as a deed for and on behalf of **BioTheryX, Inc.** by persons who, in accordance with the laws of the territory of incorporation, are acting under the authority of the company:

Signature: _____

Name: _____ Marc Philippe Drouet _____

Title: _____ President and CEO _____

Date: _____ December 21, 2021 _____

Signature: _____

Name: _____

Title: _____

Date: _____

Signed as a deed for and on behalf of **NeuroTheryX Canada Ltd.** by persons who, in accordance with the laws of the territory of incorporation, are acting under the authority of the company:

Signature: _____

Name: _____ Armen Manoukian _____

Title: _____ CEO/CSO _____

Date: _____ December 21, 2021 _____

Signature: _____

Name: _____

Title: _____

Date: _____

CONFIDENTIAL
ATTORNEY-CLIENT PRIVILEGE
ATTORNEY WORK PRODUCT

Schedule 1

Atty. Ref.	Type	Serial No.	Filed	Inventors	Title	Status	Estimated Expiration
Family 1							
12771-007-185	TW	104119644	6/17/2015	MANOUKIAN MASTRONARDI SCANGA MERCURIO CHAN	HYDROXYPYRIDONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE FOR TREATING INFLAMMATORY NEURODEGENERATIVE OR IMMUNE- MEDIATED DISEASES	Abandoned	
12771-007-228	WO	PCT/US2015/0355 06	6/12/2015	MANOUKIAN MASTRONARDI SCANGA MERCURIO CHAN	HYDROXYPYRIDONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE FOR TREATING INFLAMMATORY NEURODEGENERATIVE OR IMMUNE- MEDIATED DISEASES	Completed	
12771-007-888	US	62/014,016	6/17/2015	MANOUKIAN MASTRONARDI SCANGA MERCURIO CHAN	HYDROXYPYRIDONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE FOR TREATING INFLAMMATORY NEURODEGENERATIVE OR IMMUNE- MEDIATED DISEASES	Expired	
12771-007-999	US	14/738,652	6/12/2015	MANOUKIAN MASTRONARDI SCANGA MERCURIO CHAN	HYDROXYPYRIDONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE FOR TREATING PROLIFERATIVE DISEASES	Issued	6-12-2035
12771-013-999	US	15/389,182	12/22/2016	MANOUKIAN MASTRONARDI SCANGA MERCURIO CHAN	HYDROXYPYRIDONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE FOR TREATING PROLIFERATIVE DISEASES	Issued	6-12-2035

CONFIDENTIAL
ATTORNEY-CLIENT PRIVILEGE
ATTORNEY WORK PRODUCT

Family 2						
12771-009-888	US	62/239,783	10/9/2015	MANOUKIAN MASTRONARD I SCANGA MERCURIO CHAN	PHARMACEUTICAL COMPOSITIONS COMPRISING ONE OR MORE PYRONE COMPOUNDS, AND THEIR USE FOR TREATING INFLAMMATORY AND NEURODEGENERATIVE DISEASES	Expired
12771-009-999	US	15/288,780	10/7/2016	MANOUKIAN MASTRONARD I SCANGA MERCURIO CHAN	PHARMACEUTICAL COMPOSITIONS COMPRISING ONE OR MORE PYRONE COMPOUNDS, AND THEIR USE FOR TREATING INFLAMMATORY AND NEURODEGENERATIVE DISEASES	Pending
Family 3						
12771-012-001	CA	3,024,118	5/15/2017	FUNG SULLIVAN CHAN MERCURIO MANOUKIAN SCANGA MASTRONARD I	PYRIDINETHIONES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE FOR TREATING A PROLIFERATIVE, INFLAMMATORY, NEURODEGENERATIVE, OR IMMUNE-MEDIATED DISEASE	Pending
12771-012-007	AU	2017266878	5/15/2017	FUNG SULLIVAN CHAN MERCURIO MANOUKIAN SCANGA MASTRONARD I	PYRIDINETHIONES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE FOR TREATING A PROLIFERATIVE, INFLAMMATORY, NEURODEGENERATIVE, OR IMMUNE-MEDIATED DISEASE	Pending
12771-012-012	JP	2018-560167	5/15/2017	FUNG SULLIVAN CHAN MERCURIO MANOUKIAN SCANGA MASTRONARD I	PYRIDINETHIONES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE FOR TREATING A PROLIFERATIVE, INFLAMMATORY, NEURODEGENERATIVE, OR IMMUNE-MEDIATED DISEASE	Pending

CONFIDENTIAL
ATTORNEY-CLIENT PRIVILEGE
ATTORNEY WORK PRODUCT

12771-012-146	CN	201780043972	5/15/2017	FUNG SULLIVAN CHAN MERCURIO MANOUKIAN SCANGA MASTRONARD 1	PYRIDINETHIONES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE FOR TREATING A PROLIFERATIVE, INFLAMMATORY, NEURODEGENERATIVE, OR IMMUNE-MEDIATED DISEASE	Pending	5-15-2037
12771-012-185	TW	106115889	5/12/2017	FUNG SULLIVAN CHAN MERCURIO MANOUKIAN SCANGA MASTRONARD 1	PYRIDINETHIONES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE FOR TREATING A PROLIFERATIVE, INFLAMMATORY, NEURODEGENERATIVE, OR IMMUNE-MEDIATED DISEASE	Pending	5-15-2037
12771-012-227	EP	17725128.7	5/15/2017	FUNG SULLIVAN CHAN MERCURIO MANOUKIAN SCANGA MASTRONARD 1	PYRIDINETHIONES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE FOR TREATING A PROLIFERATIVE, INFLAMMATORY, NEURODEGENERATIVE, OR IMMUNE-MEDIATED DISEASE	Pending	5-15-2037
12771-012-228	WO	PCT/US2017/032599	5/15/2017	FUNG SULLIVAN CHAN MERCURIO MANOUKIAN SCANGA MASTRONARD 1	PYRIDINETHIONES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE FOR TREATING A PROLIFERATIVE, INFLAMMATORY, NEURODEGENERATIVE, OR IMMUNE-MEDIATED DISEASE	Completed	
12771-012-888	US	62/337,256	5/16/2016	FUNG SULLIVAN CHAN MERCURIO MANOUKIAN SCANGA	PYRIDINETHIONES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE FOR TREATING A PROLIFERATIVE, INFLAMMATORY, NEURODEGENERATIVE, OR IMMUNE-MEDIATED DISEASE	Expired	

PATENT

REEL: 058544 FRAME: 0603

CONFIDENTIAL
ATTORNEY-CLIENT PRIVILEGE
ATTORNEY WORK PRODUCT

				MASTRONARD I		
12771-012-999	US	15/595,199	5/15/2017	FUNG SULLIVAN CHAN MERCURIO MANOUKIAN SCANGA MASTRONARD I	PYRIDINETHIONES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE FOR TREATING A PROLIFERATIVE, INFLAMMATORY, NEURODEGENERATIVE, OR IMMUNE-MEDIATED DISEASE	Issued 5-15-2037
12771-034-999	US	16/298,868	3/11/2019	FUNG SULLIVAN CHAN MERCURIO MANOUKIAN SCANGA MASTRONARD I	PYRIDINETHIONES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE FOR TREATING A PROLIFERATIVE, INFLAMMATORY, NEURODEGENERATIVE, OR IMMUNE-MEDIATED DISEASE	Issued 5-15-2037

PATENT

REEL: 058544 FRAME: 0604

RECORDED: 01/04/2022